Financial & competing interests disclosure
S Jordan has research grants from CSL Behring and Genentech Inc. to conduct research in desensitization of highly-HLA sensitized patients and also owns a patent USP171,585,B1 titled “IVIG immunosuppression of highly-HLA sensitized patients”. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.